INT132178

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2005
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 41
Total Number 43
Disease Relevance 15.55
Pain Relevance 12.98

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD80) intracellular (CD80) cell-cell signaling (CD80)
Anatomy Link Frequency
CD86 15
T-cell 12
plaque 2
cytotoxic T-lymphocyte 2
B cells 1
CD80 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 983 99.98 Very High Very High Very High
rheumatoid arthritis 565 99.36 Very High Very High Very High
Inflammation 204 98.68 Very High Very High Very High
psoriasis 260 98.32 Very High Very High Very High
antagonist 22 93.76 High High
cytokine 248 92.48 High High
Arthritis 263 89.76 High High
tolerance 80 86.40 High High
Pain 51 83.92 Quite High
methotrexate 292 81.92 Quite High
Disease Link Frequency Relevance Heat
Rheumatoid Arthritis 572 99.36 Very High Very High Very High
Apoptosis 28 99.36 Very High Very High Very High
INFLAMMATION 221 98.68 Very High Very High Very High
Psoriasis 294 98.32 Very High Very High Very High
Systemic Lupus Erythematosus 14 97.84 Very High Very High Very High
Hookworm Infection 105 93.32 High High
Necrosis 42 93.00 High High
Cancer 75 92.64 High High
Disease 397 91.92 High High
Arthritis 75 89.76 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The fusion protein abatacept is a selective costimulation modulator that avidly binds to the CD80/CD86 ligands on an antigen-presenting cell, resulting in the inability of these ligands to engage the CD28 receptor on the T cell.
CD80 Binding (binds) of in CD86 associated with abatacept
1) Confidence 0.47 Published 2005 Journal J Clin Rheumatol Section Abstract Doc Link 16357751 Disease Relevance 0.59 Pain Relevance 0.52
Subsequently, there is a chain of molecular events including engagement of CD154 (CD40L) on Th2 cells and CD40 on B cells, along with engagement of CD28 and CD80/86 on Th2 and B cells respectively.
CD80 Binding (engagement) of in B cells
2) Confidence 0.47 Published 2010 Journal Allergy, Asthma & Immunology Research Section Body Doc Link PMC2946700 Disease Relevance 0.74 Pain Relevance 0.30
Abatacept is a fusion protein (cytotoxic T-lymphocyte-associated antigen-4 immunoglobulin [CTLA4Ig]); which blocks the binding of CD28 by avidly binding CD80/86.
CD80 Binding (binding) of in cytotoxic T-lymphocyte associated with abatacept
3) Confidence 0.47 Published 2007 Journal Drugs Section Abstract Doc Link 17209660 Disease Relevance 0.69 Pain Relevance 0.50
Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation.
CD80 Binding (binding) of in T-cell associated with abatacept
4) Confidence 0.47 Published 2007 Journal Adv Ther Section Abstract Doc Link 17565924 Disease Relevance 0.73 Pain Relevance 0.68
These data support the concept that abatacept therapeutic activity is primarily due to the binding to CD80/86 through the CTLA4 extracellular domain and not through activities mediated by the modified Fc domain.


CD80 Binding (binding) of
5) Confidence 0.47 Published 2007 Journal J. Rheumatol. Section Body Doc Link 17787038 Disease Relevance 0 Pain Relevance 0
While abatacept was found to bind its target receptor, CD80/86, it did not appreciably bind the low-affinity Fc receptors CD16 and CD32 as measured by flow cytometry and SPR.
CD80 Binding (bind) of
6) Confidence 0.47 Published 2007 Journal J. Rheumatol. Section Body Doc Link 17787038 Disease Relevance 0 Pain Relevance 0
Abatacept, a selective co-stimulation modulator, inhibits CD28-dependent T-cell activation by binding to CD80 and CD86 [4].
CD80 Binding (binding) of in CD86 associated with abatacept
7) Confidence 0.41 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.28 Pain Relevance 0.78
The most important ligand is CTLA-4, a well-defined down-regulator of T-cell activation, which has a much higher binding affinity for CD80/CD86 than CD28.
CD80 Binding (binding) of in T-cell
8) Confidence 0.36 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727897 Disease Relevance 0.30 Pain Relevance 0.64
Abatacept binds to CD80/CD86 on antigen-presenting cells thus blocking the co-stimulatory signal to the naïve T cells and interfering with a central inflammatory rheumatoid arthritis signal pathway.
CD80 Binding (binds) of in T cells associated with inflammation, rheumatoid arthritis and abatacept
9) Confidence 0.36 Published 2009 Journal Ugeskr. Laeg. Section Abstract Doc Link 19174034 Disease Relevance 0.26 Pain Relevance 0.40
CTLA-4 is a regulator of co-stimulation and inhibits the activation of T cells through interfering with the interaction of CD80/86 on antigen-presenting cells with CD28 on T cells.
CD80 Binding (interaction) of in T cells
10) Confidence 0.36 Published 2008 Journal Ann. Rheum. Dis. Section Abstract Doc Link 18203760 Disease Relevance 0.13 Pain Relevance 0
The new biological agent abatacept, a recombinant protein consisting of the extracellular region of the human cytotoxic T-lymphocyte-associated antigen (CTLA)-4 receptor fused to the constant fragment (Fc) region of IgG1, binds to the CD80/CD86 molecules on antigen-presenting cells and modulates T-cell activation.
CD80 Binding (binds) of in T-cell associated with abatacept
11) Confidence 0.35 Published 2009 Journal Clin Drug Investig Section Abstract Doc Link 19243211 Disease Relevance 0.85 Pain Relevance 0.81
It selectively modulates the co-stimulatory pathway of T-cell activation by preventing the engagement of CD80/CD86 on APCs with CD28 on T cells.
CD80 Binding (engagement) of in CD86
12) Confidence 0.35 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2582809 Disease Relevance 0.45 Pain Relevance 0.50
The detailed consequences of blocking the interaction between CD80/86 and CD28 in RA still require study, in particular because co-stimulatory pathways other than CD28-mediated ones remain unaffected.
CD80 Binding (interaction) of associated with rheumatoid arthritis
13) Confidence 0.35 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833982 Disease Relevance 0.81 Pain Relevance 0.46
While abatacept was found to bind its target receptor, CD80/86, it did not appreciably bind the low-affinity Fc receptors CD16 and CD32 as measured by flow cytometry and SPR.
CD80 Neg (not) Binding (bind) of
14) Confidence 0.35 Published 2007 Journal J. Rheumatol. Section Body Doc Link 17787038 Disease Relevance 0 Pain Relevance 0
An example is abatacept (soluble cytotoxic-T-lymphocyte-associated protein 4-immunoglobulin), which binds with high affinity to CD80/CD86 and effectively suppresses inflammatory activity in RA.
CD80 Binding (binds) of in T-lymphocyte associated with inflammation, rheumatoid arthritis and abatacept
15) Confidence 0.35 Published 2006 Journal Nature clinical practice. Rheumatology Section Abstract Doc Link 16932686 Disease Relevance 0.83 Pain Relevance 0.40
Furthermore, no gene changes were observed in response to belatacept, a modified version of abatacept that binds with higher avidity to CD80 and CD86.
CD80 Binding (binds) of in CD86
16) Confidence 0.33 Published 2009 Journal J. Clin. Immunol. Section Body Doc Link 19259798 Disease Relevance 0 Pain Relevance 0
BACKGROUND: It has been proposed that ligation of CD80 and CD86 induces reverse signaling into antigen-presenting cells.
CD80 Binding (ligation) of in CD86
17) Confidence 0.33 Published 2009 Journal J. Clin. Immunol. Section Abstract Doc Link 19259798 Disease Relevance 0 Pain Relevance 0.17
The second, or co-stimulatory, signal is delivered following the engagement of CD80/CD86 on antigen-presenting cells with a cognate receptor, CD28, on the surface of the T cell [6,7].
CD80 Binding (engagement) of in T cell
18) Confidence 0.32 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.29 Pain Relevance 0.69
Its binding avidity to CD80 and CD86 was twofold and fourfold higher, respectively, and inhibition of T-cell activation was tenfold more powerful than those of CTLA4-Ig.
CD80 Binding (binding) of in CD86
19) Confidence 0.30 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721321 Disease Relevance 0.17 Pain Relevance 0.14
B7/CTLA-4 interactions and regulatory T-cells
B7 Binding (interactions) of in regulatory T-cells
20) Confidence 0.26 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721321 Disease Relevance 0.06 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox